Stock to Focus: Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

0
79

Raptor Pharmaceutical Corp. (NASDAQ:RPTP):
The Company gained 2.93% and finished at $4.92. The daily volume was measured at 986,915.00 shares. The 52-week high of the share price is $16.28 and the 52-week low is $2.94. The company has a market cap of $425.04 million. Its latest closing price has a distance of 3.35% from SMA20 and is 4.42% up than SMA50. The stock currently has Price to Sales (P/S) value of 4.02 where Price to Book (P/B) value stands at 5.35. The company is currently showing ROA (Return on Assets) value of -26.80% where ROE (Return on Equity) is -81.60%. Return on equity (ROE) measures the rate of return on the ownership interest (shareholders’ equity) of the common stock owners. It measures a firm’s efficiency at generating profits from every unit of shareholders’ equity (also known as net assets or assets minus liabilities).

By looking at Raptor Pharmaceutical Corp. (NASDAQ:RPTP) YTD (year to date) performance, the stock shows Negative value of -5.38%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is appreciating.

The High price target of the company’s Share is at $11.00 based on the calculations and analysis of 6 brokers. According to the analysts, the company has the Low Price target of $4.00 whereas, the Mean Target is estimated by the brokers is $7.33.

For an overview on Recommendation Trends, 2 Analysts assigned the stock as Strong Buy. 2 said it’s a Buy, 3 assigned Hold rating where 0 stated the stock as Underperform and 0 marked the stock as Sell.

Most Recent Upgrades & Downgrades for Raptor Pharmaceutical Corp. (NASDAQ:RPTP) was initiated On April 7.2016 where JMP Securities “Upgrade” the stock from “Mkt Perform” to “Mkt Outperform”.

While Looking at the Analyst Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as $-0.17 by 7.00 analysts. They are also projecting the Low EPS estimate as $-0.20 as compared to the Higher EPS estimate of $-0.14.

Now when we talk about Revenue Estimate for the current Fiscal Quarter, Average Revenue Estimate of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) is projected as $29.08 million where Low Revenue estimate and High Revenue Estimate are $27.80 Million and $30.50 million respectively by 6 Analysts.

The EPS (Earnings per share) Trend for the current Quarter is estimated at $-0.17 per share while the Trend for 7 days ago was $-0.17. The EPS Trend for 30, 60 and 90 Days ago were $-0.17, $-0.17 and $-0.15.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Profile:

Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults, as well as in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. It also provides QUINSAIR, a formulation of the antibiotic drug levofloxacin for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients in Canada and Europe. The company’s clinical development programs include RP103 that is used as a treatment for Huntington’s disease; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. Its preclinical product candidates include RP105 and RP106 for various rare diseases. Raptor Pharmaceuticals Corp. has a license agreement with University of California. The company was founded in 2005 and is headquartered in Novato, California.